Compile Data Set for Download or QSAR
Report error Found 58 Enz. Inhib. hit(s) with Target = 'Cyclin-dependent kinase 3/G1/S-specific cyclin-E1'
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601933(US11643416, Compound 1 | 4-((6'-hydroxy-8'-oxo-7',...)
Affinity DataIC50: 0.940nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM2579(CHEMBL388978 | Staurosporine, 8 | Staurosporin, 4 ...)
Affinity DataIC50: 1.70nMAssay Description:Inhibition of human CDK3/cyclin-E using histone H1 as substrate by [gamma-33P]-ATP assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM50193093(RGB-286638)
Affinity DataIC50: 2nMAssay Description:Inhibition of CDK3/cyclin E (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/2/2018
Entry Details Article
PubMed
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM2579(CHEMBL388978 | Staurosporine, 8 | Staurosporin, 4 ...)
Affinity DataIC50: 2.10nMAssay Description:Inhibition of human CDK3/cyclin-E using histone H1 as substrate by [gamma-33P]-ATP assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2021
Entry Details Article
PubMed
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM2579(CHEMBL388978 | Staurosporine, 8 | Staurosporin, 4 ...)
Affinity DataIC50: 2.10nMAssay Description:Inhibition of human CDK3/cyclin-E using histone H1 as substrate by [gamma-33P]-ATP assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2021
Entry Details Article
PubMed
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601934(US11643416, Compound 2 | 4-((7'-oxo-7',8'-dihydro-...)
Affinity DataIC50: 2.80nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM2579(CHEMBL388978 | Staurosporine, 8 | Staurosporin, 4 ...)
Affinity DataIC50: 2.90nMAssay Description:Inhibition of human CDK3/cyclin-E using histone H1 as substrate by [gamma-33P]-ATP assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/19/2021
Entry Details Article
PubMed
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM50363196(CHEMBL1944698)
Affinity DataIC50: 3nMAssay Description:Inhibition of recombinant human full length C-terminal His6-tagged CDK3/N-terminal GST-tagged cyclin E expressed in baculovirus infected Sf21 insect ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/2/2018
Entry Details Article
PubMed
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM50059889(3-methoxy-2-methyl-4-methylamino-(2S,3S,4S,6R)-29-...)
Affinity DataIC50: 4nMAssay Description:Inhibition of CDK3/Cyclin E (unknown origin)-mediated phosphorylation of peptide substrate incubated for 15 mins prior to substrate addition measured...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/12/2014
Entry Details Article
PubMed
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601936(US11643416, Compound 4 | 4-((1'H-spiro[cyclohexane...)
Affinity DataIC50: 5nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601941(US11643416, Compound 23 | (S)-4-((6'-(fluoromethyl...)
Affinity DataIC50: 6nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601953(US11643416, Compound 55 | 2'-((4-(piperazine-1- ca...)
Affinity DataIC50: 6nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM50363196(CHEMBL1944698)
Affinity DataIC50: 8nMAssay Description:Inhibition of C-terminal His6-tagged human CDK3/N-terminal GST-tagged human cyclin EMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/25/2022
Entry Details Article
PubMed
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601952(US11643416, Compound 54 | 2'-((4-(4-methylpiperazi...)
Affinity DataIC50: 8nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM50363196(CHEMBL1944698)
Affinity DataIC50: 8nMAssay Description:Inhibition of recombinant human full-length C-terminal His6-tagged CDK3/full-length human N-terminal GST-tagged Cyclin E expressed in baculovirus inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2021
Entry Details Article
PubMed
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM59227(Pyrazolopyrimidone analog, RGB-286147)
Affinity DataIC50: 9nMAssay Description:Inhibition of in vitro kinase activity of purified CDKs.More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2011
Entry Details Article
PubMed
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM50511926(CHEMBL4442620)
Affinity DataIC50: 9nMAssay Description:Inhibition of recombinant human full-length C-terminal His6-tagged CDK3/full-length human N-terminal GST-tagged Cyclin E expressed in baculovirus inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2021
Entry Details Article
PubMed
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601935(US11643416, Compound 3 | 4-((3'-oxo-2',3'-dihydro-...)
Affinity DataIC50: 9.90nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601951(US11643416, Compound 53 | 6'-hydroxy-2'-((4-(4- me...)
Affinity DataIC50: 10nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601942(US11643416, Compound 42 | 4-((8'-methyl-7'-oxo-7',...)
Affinity DataIC50: 10nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM50573929(CHEMBL4848734)
Affinity DataIC50: 11nMAssay Description:Inhibition of human CDK3/cyclinE using Histone H1 as substrate incubated for 2 hrs by [gamma-33P]-ATP assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/23/2022
Entry Details Article
PubMed
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601946(US11643416, Compound 46 | 4-((1',3'-dimethyl-1'H- ...)
Affinity DataIC50: 13nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601938(US11643416, Compound 18 | (R)-4-((6'-(fluoromethyl...)
Affinity DataIC50: 18nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601940(US11643416, Compound 5 | 4-((1'-methyl-1'H-spiro[c...)
Affinity DataIC50: 23nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601949(US11643416, Compound 51 | 2'-((4-((4-methylpiperaz...)
Affinity DataIC50: 23nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601948(US11643416, Compound 50 | 6'-hydroxy-2'-((4-((4- m...)
Affinity DataIC50: 28nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601944(US11643416, Compound 43 | 4-((6',8'-dimethyl-7'-ox...)
Affinity DataIC50: 29nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601939(US11643416, Compound 19 | (S)-4-((6'-methyl-8'-oxo...)
Affinity DataIC50: 34nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM50433369(CHEMBL2377825)
Affinity DataIC50: 38nMAssay Description:Inhibition of CDK3/Cyclin E (unknown origin)-mediated phosphorylation of peptide substrate incubated for 15 mins prior to substrate addition measured...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/12/2014
Entry Details Article
PubMed
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM50573930(CHEMBL4856177)
Affinity DataIC50: 51nMAssay Description:Inhibition of human CDK3/cyclinE using Histone H1 as substrate incubated for 2 hrs by [gamma-33P]-ATP assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/23/2022
Entry Details Article
PubMed
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM2579(CHEMBL388978 | Staurosporine, 8 | Staurosporin, 4 ...)
Affinity DataIC50: 54nMAssay Description:Inhibition of full length human recombinant CDK3/Cyclin E using histone H1 as substrate incubated for 40 mins in presence of [gamma-33ATP] by radiome...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/24/2022
Entry Details Article
PubMed
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601954(US11643416, Compound 59 | 8'-methyl-2'-((4-((4-met...)
Affinity DataIC50: 57nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601955(US11643416, Compound 61 | 7'-((4-(piperazine-1- ca...)
Affinity DataIC50: 58nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601937(US11643416, Compound 12 | 4-((1'-methyl-3'-oxo-2',...)
Affinity DataIC50: 59nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601945(US11643416, Compound 45 | 4-((3'-methyl-1'H-spiro[...)
Affinity DataIC50: 73nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601950(US11643416, Compound 52 | 7'-((4-(4-methylpiperazi...)
Affinity DataIC50: 75nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM164883(US9067888, 33)
Affinity DataIC50: 94nMAssay Description:Inhibition of recombinant human CDK3/cyclin E expressed in baculovirus infected Sf9 insect cells after 80 mins in presence of [33P]ATP by microbeta s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/2/2018
Entry Details Article
PubMed
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601957(US11643416, Compound 63 | 4-((3'-oxo-2',3'-dihydro...)
Affinity DataIC50: 96nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601958(US11643416, Compound 64 | N-methyl-4-((3'-oxo-2',3...)
Affinity DataIC50: 105nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601961(US11643416, Compound 74 | 7'-((4-(morpholine-4- ca...)
Affinity DataIC50: 106nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM50563486(CHEMBL4757951)
Affinity DataIC50: 113nMAssay Description:Inhibition of CDK3/cyclin E1 (unknown origin) using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2022
Entry Details Article
PubMed
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601947(US11643416, Compound 49 | 7'-((4-((4-methylpiperaz...)
Affinity DataIC50: 115nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM50552007(CHEMBL4796925)
Affinity DataIC50: 117nMAssay Description:Inhibition of full length human recombinant CDK3/Cyclin E using histone H1 as substrate incubated for 40 mins in presence of [gamma-33ATP] by radiome...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/24/2022
Entry Details Article
PubMed
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601956(US11643416, Compound 62 | N,N-dimethyl-4-((3'-oxo-...)
Affinity DataIC50: 187nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM50113281(AT-7519 | US20240293557, Compound AMC-3-098 | US12...)
Affinity DataIC50: 360nMAssay Description:Inhibition of CDK3/cyclin E (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2022
Entry Details Article
PubMed
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM50113281(AT-7519 | US20240293557, Compound AMC-3-098 | US12...)
Affinity DataIC50: 360nMAssay Description:Inhibition of CDK3/cyclin E1 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2022
Entry Details Article
PubMed
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM50113281(AT-7519 | US20240293557, Compound AMC-3-098 | US12...)
Affinity DataIC50: 360nMAssay Description:Inhibition of recombinant human full-length C-terminal His6-tagged CDK3/full-length human N-terminal GST-tagged Cyclin E expressed in baculovirus inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2021
Entry Details Article
PubMed
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM50539904(CHEMBL4647764)
Affinity DataIC50: 366nMAssay Description:Inhibition of kinase tracer 236 binding to recombinant human full-length N-terminal GST-tagged CDK3/cyclin E1 expressed in baculovirus expression sys...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2021
Entry Details Article
PubMed
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM50561527(CHEMBL4764481)
Affinity DataIC50: 399nMAssay Description:Inhibition of CDK3/cyclinE (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/28/2022
Entry Details Article
PubMed
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM168383(US9669034, 2 (rac)-4-(4-Fluoro-2-methoxyphenyl)-N-...)
Affinity DataIC50: 890nMAssay Description:Inhibition of C-terminal His6-tagged human CDK3/N-terminal GST-tagged human cyclin E expressed in baculovirus infected Sf21 insect cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/25/2022
Entry Details Article
PubMed
Displayed 1 to 50 (of 58 total ) | Next | Last >>
Jump to: